29th January – February 1st 2019

Paris, France


Why choose the Microbiome Drug Development Summit

Recent breakthroughs in DNA sequencing, metagenomic analysis and computational techniques have given scientists new insight into the structure and function of the human microbiota, an interconnected community of symbiotic, commensal and pathogenic microorganisms. As valuable clinical data solidifies the importance of the human microbiome on human health and disease, recent efforts have sought to harness this research to create microbiome-based therapeutics.

Situated at the heart of therapeutic R&D, the Microbiome Drug Development Summit kick starts 2018, once again to help large pharma, biotech and academic institutions accelerate the discovery, clinical development of safe, effective and commercially scalable microbiome therapeutics across a broad range of disease indications.

Set to tackle the greatest scientific, regulatory, clinical, manufacturing and commercialization challenges across the entire drug development value chain, Microbiome Drug Development Summit Europe will showcase leading industry case studies focused on enhancing the application of novel technologies to standardise results, accelerate target discovery and optimise the translation of microbiome research into safe and effective therapeutic products.

What’s new for 2018

End-to-End Drug Development Focus – From start to finish, the Microbiome Drug Development Summit is carefully positioned to solutions across the entire drug development value chain from discovery/target validation, preclinical development, clinical trial execution to scaling up effectively for commercially viable microbiome-based therapeutics.

Overcome Unique Product Development Challenges with Support from Industry – As leading drug developers battle with clinical trial design challenges, regulatory uncertainty and manufacturing/CMC complexities, Microbiome Drug Development Summit will integrate specific expertise to better these unique challenges facing the Microbiome community.

Learn How Pharmaceutical Giants are viewing the Therapeutic potential of the Human Microbiome – Numerous partnerships between large pharmaceutical companies and microbiome-focused biotech are being made. With insight from Merck, AstraZeneca, GSK and Ferring Pharmaceuticals, learn how these companies are leveraging their resources to take early product ideas and accelerate them towards market approval.

Dedicated Day Focused on the Human Microbiome’s Impact within Immuno-Oncology – Research has proven that the gut microbiota and their associated metabolites strongly influence the immune system in both health and disease. In collaboration with our keynote speaker and chairperson, Prof. Laurence Zitvogel, learn how the microbiome can be leveraged to improve response rates of immunotherapies whilst providing a new way to control the efficacy and toxicity of successful cancer therapeutics.

Novel Modalities in Microbiome Therapeutics – Efforts in developing a microbiome-based therapeutic can be classified into three broad categories: additive, subtractive or modulatory therapies. Microbiome Drug Development Summit Europe provides a unique platform to discuss insights across a broad range of modalities that show the potential of translating the microbiota into real-world therapies.

To discover a broad range of case studies directly related to the microbiome’s impact on drug development, take a look at the event guide:

Where to find more information?